At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 10 enrolled
Drug / intervention
Brentuximab vedotindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4, Single Arm, Open Label, Multicenter Study of Brentuximab Vedotin Treatment of Chinese Patients With CD30-Positive Cutaneous T-Cell Lymphoma
In Brief
A Phase 4 clinical trial evaluating Brentuximab vedotin for T-Cell Lymphoma. Completed, enrolled 10 participants across 4 sites.
Detailed Summary
The main aim is to check the long-term side effects of treatment with Brentuximab Vedotin and to see if that treatment improves symptoms of cluster of differentiation antigen 30 (CD30-Positive) Cutaneous T-Cell Lymphoma in Chinese adults. Participants will receive brentuximab vedotin through the vein on day 1 of each 21 day cycle up to maximum 16 cycles.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsT-Cell Lymphoma
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
2023202420252026
First PostedJul 2022
Enrollment StartNov 2022
Primary CompletionAug 2024
TodayJul 2026
First PostedJul 5, 2022
Enrollment StartNov 28, 2022
Primary CompletionAug 9, 2024
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 4.0 years ago
Interventions
Brentuximab vedotindrug
Brentuximab vedotin IV infusion.